Formula I Antiretroviral Compounds for Drug-Resistant HIV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatments require daily medication and face challenges with drug-resistant HIV strains, necessitating the development of new antiretroviral agents with improved pharmacokinetic properties and reduced dosing frequency.
Innovation Solution
Development of novel compounds represented by Formula I, which can be administered less frequently and are effective against drug-resistant HIV strains, including pharmaceutically acceptable salts and compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly active antiretroviral therapies (HAART) are used to treat HIV-1 infections, then viral load is reduced and disease progression is delayed, but HIV strains resistant to current therapies emerge
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of antiretroviral compounds through various substituents (R1-R6, X groups) to create novel analogs with improved activity against drug-resistant HIV strains. The systematic variation of molecular parameters enables the development of compounds that overcome resistance mechanisms while maintaining therapeutic effectiveness.
2Reliability
If current HIV treatment regimens are administered, then viral replication is controlled, but patients must take medication daily for their lifetime
Solution Approach 1:
The patent applies dynamics by designing compounds with optimized pharmacokinetic properties including extended half-life and sustained release characteristics. The molecular structures are engineered to maintain therapeutic levels over extended periods, enabling less frequent dosing while ensuring continuous viral control throughout the treatment duration.
Solution Approach 2:
The patent modifies pharmacokinetic parameters through chemical structure optimization, adjusting lipophilicity, molecular weight, and metabolic stability to achieve prolonged drug circulation and reduced clearance rates, thereby extending the interval between dosing events.
3Loss of time
If novel compounds with improved pharmacokinetic properties are developed, then dosing frequency can be reduced, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into modular functional groups and building blocks that can be systematically combined. This modular approach allows for structured exploration of chemical space while maintaining synthetic feasibility, breaking down the complex design challenge into manageable sub-components with specific functions.
Data Source
AI summary
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.